MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
Cancer Letters · 2026-12 · 662 · 218927
DOI: 10.1016/j.canlet.2026.218927 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Christabelle Rajesh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, U…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Macrophages, Membrane Proteins, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, American Cancer Society Inc, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Mucin-16 (MUC16) is overexpressed in >60% of pancreatic ductal adenocarcinoma (PDAC) cases and correlates with poor outcomes, yet its role in regulating tumor-immune interactions remains incompletely defined. Using KPC and KPC-MUC16 knockout (KPC-MUC16KO) genetically engineered and orthotopic mouse models, we show that loss of MUC16 markedly reduces tumor burden and reprograms the tumor microenvironment (TME) toward a less immunosuppressive state. MUC16 deficiency significantly decreased CD206+ and Ym1/2+ M2-like macrophages, increased the M1/M2 ratio, and improved survival. Cytokine profiling identified CCL2 and Serpin-E1 as MUC16- dependent secreted factors that promote macrophage recruitment and polarization; neutralization of these cytokines reduced macrophage migration in vitro. Bone marrow-derived macrophages (BMDM) exposed to MUC16-expressing tumor cells or conditioned media adopted a CD206+Arg1+ M2-like phenotype, whereas MUC16KO tumor signals favored inflammatory CD86+iNOS + M1-like polarization. Macrophage depletion using clodronate liposomes significantly impaired tumor growth in MUC16-competent tumors but had minimal effect in KPC-MUC16KO tumors, indicating dependence on macrophage-mediated immunosuppression in the former group. Spatial transcriptomics revealed a globally distinct TME in MUC16KO tumors, including enhanced antigen-presentation programs, increased complement activation, and fibroblast states skewed toward pro-inflammatory signaling. These findings establish MUC16 as a key orchestrator of macrophage-driven immunosuppression in PDAC and support therapeutic strategies combining MUC16-targeted interventions with TME-reprogramming approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
- College of Public Health, Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pharmacology and Toxicology, University of Louisville, School of Medicine, Louisville, KY, 40202, USA; UofL Health - Brown Cancer Center, University of Louisville, School of Medicine, Louisville, KY, USA.
- Department of Pharmacology and Toxicology, University of Louisville, School of Medicine, Louisville, KY, 40202, USA; UofL Health - Brown Cancer Center, University of Louisville, School of Medicine, Louisville, KY, USA.…
Förderung
- NCI NIH HHS
- American Cancer Society Inc
- National Institutes of Health National Cancer Institute
Zitieren
APA
Rajesh, C., Sagar, S., Huang, Y., Mundry, C. S., Chaitankar, V., Shah, O. S., Sumeet, C., Caffrey, T., O'Connell, K. A., Swanson, B., Yu, F., Behringer, R. R., Prathapan, A., Hollingsworth, M. A., & Radhakrishnan, P. (2026). MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. Cancer Letters, 662, 218927. https://doi.org/10.1016/j.canlet.2026.218927
Vancouver
Rajesh C, Sagar S, Huang Y, Mundry CS, Chaitankar V, Shah OS, et al. MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. Cancer Letters. 2026;662:218927. doi:10.1016/j.canlet.2026.218927
BibTeX
@article{Rajesh2026,
author = {Rajesh, Christabelle and Sagar, Satish and Huang, Ying and Mundry, Clara S and Chaitankar, Vijender and Shah, Osama Shiraz and Sumeet, Charitha and Caffrey, Thomas and O'Connell, Kelly A and Swanson, Benjamin and Yu, Fang and Behringer, Richard R and Prathapan, Abeesh and Hollingsworth, Michael A and Radhakrishnan, Prakash},
title = {MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer},
journal = {Cancer Letters},
year = {2026},
volume = {662},
pages = {218927},
doi = {10.1016/j.canlet.2026.218927}
}
EUVIMED